Shares of Vericel Corp (NASDAQ:VCEL) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $17.07 and traded as high as $18.77. Vericel shares last traded at $18.47, with a volume of 17,974 shares.
A number of analysts have recently issued reports on the stock. ValuEngine upgraded shares of Vericel from a “hold” rating to a “buy” rating in a report on Monday, November 25th. BidaskClub upgraded shares of Vericel from a “hold” rating to a “buy” rating in a research note on Tuesday, October 29th. Zacks Investment Research reiterated a “buy” rating and set a $16.00 target price on shares of Vericel in a report on Saturday, October 12th. HC Wainwright started coverage on Vericel in a research report on Wednesday, October 9th. They set a “buy” rating and a $19.00 price target for the company. Finally, BTIG Research set a $24.00 price target on Vericel and gave the company a “buy” rating in a research report on Monday, August 12th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $21.78.
The company has a quick ratio of 6.48, a current ratio of 6.93 and a debt-to-equity ratio of 0.26. The firm has a 50 day simple moving average of $17.62 and a 200-day simple moving average of $17.07. The stock has a market cap of $832.66 million, a P/E ratio of -132.14 and a beta of 2.72.
In other Vericel news, CEO Dominick Colangelo sold 58,125 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $14.88, for a total transaction of $864,900.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Michael Halpin sold 15,047 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $18.53, for a total transaction of $278,820.91. The disclosure for this sale can be found here. Insiders own 4.50% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Waddell & Reed Financial Inc. acquired a new stake in Vericel during the second quarter worth approximately $38,159,000. Nuveen Asset Management LLC acquired a new stake in shares of Vericel during the 2nd quarter worth $16,152,000. Fort Washington Investment Advisors Inc. OH acquired a new stake in shares of Vericel during the 2nd quarter worth $11,655,000. GW&K Investment Management LLC bought a new position in shares of Vericel in the second quarter worth $11,364,000. Finally, Calamos Advisors LLC bought a new position in shares of Vericel in the second quarter worth $7,572,000. Institutional investors own 86.86% of the company’s stock.
Vericel Company Profile (NASDAQ:VCEL)
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.
See Also: What is a Lock-Up Period?
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.